Goodwin advised Cerba Healthcare, a leading medical biology group based in France, on the closing of its cross-border acquisition of MenaLabs, a group of medical biology laboratories located in the United Arab Emirates. The terms of the transaction were not disclosed.
Cerba will acquire a majority stake in MenaLabs’ group. The combined innovation platform will give both companies the opportunity to offer new biomarkers and new services addressing the area’s medical and economic needs.
Operating in the medical biology tests market, in private and public sectors and clinical trials, Cerba has almost 4,200 employees including 350 biologists. It has a presence in three complementary segments, including routine medical biology, clinical trial biology and specialist medical biology.
Founded in 2014 by a team with over 20 years of experience in managing laboratories, MenaLabs is a group of medical biology laboratories located in the United Arab Emirates. With laboratories in Dubai, Sharjah and Abu Dhabi, MenaLabs has also taken over the management of a one-day surgery hospital in Abu Dhabi and has recently opened a veterinary laboratory in Sharjah dedicated to equine requirements operating 24/7.
Goodwin’s team advising Cerba Healthcare included partner William Robert.
For more information on the transaction, please view the press release.